The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates, of which two drug candidates are in Phase III stage of development, while five drug candidates are in Phase II stage, one drug candidate is in Phase I stage, 10 drug candidates are in Pre-Clinical stage and four drug candidates are in the Discovery stage. Candidiasis is a common type of fungal infection caused by fungus known as candida. Candida is found in various parts of human body including mouth, skin or belly and is non-infectious until it gets right environment to multiply and grow uncontrollably. This result in occurring of the infection, known as candidiasis.
As per the findings of the research, around 27.0% drug candidates of candidiasis pipeline are being developed to be administered by oral route, 9.0% by topical route and 27.0% are to be administered by other routes, which includes intravenous, inhalation and intramuscular. Route of administration of around 37.0% drug candidates of candidiasis pipeline was not disclosed.
The research also found that various companies received many designations from the U.S. Food and Drug Administration (USFDA) for the development of candidiasis therapeutics pipeline. In May 2016, USFDA granted the orphan drug designation to SCY-078 for the treatment of invasive candida infections, including candidemia. In January 2016, USFDA granted both fast track and qualified infectious disease product (QIDP) designations for the intravenous formulation of SCY-078 for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.
Some of the key players developing drugs for the treatment of candidiasis include Seren Pharmaceuticals, Inc., SCYNEXIS, Inc., Matinas Biopharma Holdings, Inc., Viamet Pharmaceuticals, Inc., NovaDigm Therapeutics, Inc., iCo Therapeutics, Inc., NovaBiotics Ltd., Bionex Pharmaceuticals LLC, Wellstat Therapeutics Corporation, Sealife Pharma GmbH and TGV-inhalonix.
News Courtesy: P&S Market Research